Drugs / Cinaciguat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01064037 | Apr 2010 → Feb 2011 | heart failure | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT01067859 | Mar → Sep 2010 | heart failure | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT01065077 | Mar 2010 → Jan 2011 | heart failure | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT00559650 | Dec 2007 → Feb 2009 | congestive heart failure | Bayer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cinaciguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00559650 ↗ |
| Known as | BAY 58-2667 | “AIMS: Cinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator.” PMID 22778174 ↗ Jul 20123“Cinaciguat (BAY58-2667)” NCT00559650 ↗ “Cinaciguat (BAY58-2667)” NCT01065077 ↗ “Cinaciguat (BAY58-2667)” NCT01064037 ↗ |
| Action | Activate | “soluble guanylate cyclase activator” PMID 22778174 ↗ Jul 2012 |
| Modality | Small molecule | — CHEMBL1236936 ↗ |
| Route | Intravenous | “given intravenously” NCT00559650 ↗ |